SCHEMBL4242067

SCHEMBL4242067

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(C(N)=O)cc2)c(C(=O)NC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.48
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
BRAF P15056 7/20 0.41
HDAC1 Q13547 7/20 0.41
HDAC3 O15379 4/20 0.41
HDAC4 P56524 4/20 0.41
HDAC7 Q8WUI4 4/20 0.41
HDAC2 Q92769 4/20 0.41
HDAC10 Q969S8 4/20 0.41
HDAC11 Q96DB2 4/20 0.41
HDAC8 Q9BY41 4/20 0.41
HDAC6 Q9UBN7 4/20 0.41
HDAC9 Q9UKV0 4/20 0.41
HDAC5 Q9UQL6 4/20 0.41
RAF1 P04049 1/20 0.40
ARAF P10398 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237333 0.90 PKM (0.50) PKMTAS1R3TAS1R1BRAFHDAC1
SCHEMBL4686268 0.88 PKM (0.53) PKMTAS1R3TAS1R1BRAFHDAC1
SCHEMBL4229112 0.84 PKM (0.57) PKMTAS1R3TAS1R1SMN1; SMN2NPC1
SCHEMBL4236662 0.83 PKM (0.50) PKMTAS1R3TAS1R1SMN1; SMN2NPC1
SCHEMBL4238103 0.83 PKM (0.42) PKMTAS1R3TAS1R1BRAFHDAC1
SCHEMBL4686066 0.83 HDAC1 (0.49) HDAC1HDAC2SMN1; SMN2NPC1RAB9A
SCHEMBL4236704 0.82 PKM (0.66) PKMTAS1R3TAS1R1SMN1; SMN2NPC1
SCHEMBL4235398 0.81 PKM (0.55) PKMTAS1R3TAS1R1SMN1; SMN2NPC1
SCHEMBL5149824 0.80 PKM (0.49) PKMTAS1R3TAS1R1BRAFHDAC1
SCHEMBL5149411 0.79 PKM (0.52) PKMTAS1R3TAS1R1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.